3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH

US10112931B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Thomas Raymond Caferro · Abington, US
• Zhuoliang Chen · Cambridge, US
• Young Shin Cho · Cambridge, US
• Abran Q. Costales · Corona, US
• Julian Levell · Arlington, US
• Gang Liu · Sugar Land, US
• James R. MANNING · Pleasant Hill, US
• Martin Sendzik · Belmont, US
• Cynthia Shafer · El Sobrante, US
• Michael David Shultz · Lexington, US
• James Sutton · Princeton Junction, US
• Yaping Wang · Cambridge, US
• Qian Zhao · Louisville, US

Key dates

• Filing date: Apr 27, 2017
• Grant date: Oct 30, 2018
• Expiry date: Apr 27, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.